In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations - PubMed (original) (raw)

In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations

W Kimryn Rathmell et al. Cancer Res. 2004.

Abstract

Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene cause tissue-specific tumors, with a striking genotype-phenotype correlation. Loss of VHL expression predisposes to hemangioblastoma and clear cell renal cell carcinoma, whereas specific point mutations predispose to pheochromocytoma, polycythemia, or combinations of hemangioblastoma, renal cell carcinoma, and/or pheochromocytoma. The VHL protein (pVHL) has been implicated in many cellular activities including the hypoxia response, cell cycle arrest, apoptosis, and extracellular matrix remodeling. We have expressed missense pVHL mutations in Vhl(-/-) murine embryonic stem cells to test genotype-phenotype correlations in euploid cells. We first examined the ability of mutant pVHL to direct degradation of the hypoxia inducible factor (HIF) subunits HIF1alpha and HIF2alpha. All mutant pVHL proteins restored proper hypoxic regulation of HIF1alpha, although one VHL mutation (VHL(R167Q)) displayed impaired binding to Elongin C. This mutation also failed to restore HIF2alpha regulation. In separate assays, these embryonic stem cells were used to generate teratomas in immunocompromised mice, allowing independent assessment of the effects of specific VHL mutations on tumor growth. Surprisingly, teratomas expressing the VHL(Y112H) mutant protein displayed a growth disadvantage, despite restoring HIFalpha regulation. Finally, we observed increased microvessel density in teratomas derived from Vhl(-/-) as well as VHL(Y112H), VHL(R167Q), and VHL(R200W) embryonic stem cells. Together, these observations support the hypothesis that pVHL plays multiple roles in the cell, and that these activities can be separated via discrete VHL point mutations. The ability to dissect specific VHL functions with missense mutations in a euploid model offers a novel opportunity to elucidate the activities of VHL as a tumor suppressor.

PubMed Disclaimer

Cited by

VHL suppresses UBE3B-mediated breast tumor growth and metastasis.
Wang S, Li H, Liu X, Yin T, Li T, Zheng M, Liu M, Meng X, Zhou J, Wang Y, Chen Y. Wang S, et al. Cell Death Dis. 2024 Jun 24;15(6):446. doi: 10.1038/s41419-024-06844-x. Cell Death Dis. 2024. PMID: 38914543 Free PMC article.
VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.
Rathmell WK, Chen S. Rathmell WK, et al. Expert Rev Anticancer Ther. 2008 Jan;8(1):63-73. doi: 10.1586/14737140.8.1.63. Expert Rev Anticancer Ther. 2008. PMID: 18095884 Free PMC article. Review.
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.
Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL. Gordan JD, et al. Cancer Cell. 2008 Dec 9;14(6):435-46. doi: 10.1016/j.ccr.2008.10.016. Cancer Cell. 2008. PMID: 19061835 Free PMC article.
Biology of hypoxia-inducible factor-2alpha in development and disease.
Patel SA, Simon MC. Patel SA, et al. Cell Death Differ. 2008 Apr;15(4):628-34. doi: 10.1038/cdd.2008.17. Epub 2008 Feb 15. Cell Death Differ. 2008. PMID: 18259197 Free PMC article. Review.
Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis.
Couvé S, Ladroue C, Laine E, Mahtouk K, Guégan J, Gad S, Le Jeune H, Le Gentil M, Nuel G, Kim WY, Lecomte B, Pagès JC, Collin C, Lasne F, Benusiglio PR, Bressac-de Paillerets B, Feunteun J, Lazar V, Gimenez-Roqueplo AP, Mazure NM, Dessen P, Tchertanov L, Mole DR, Kaelin W, Ratcliffe P, Richard S, Gardie B. Couvé S, et al. Cancer Res. 2014 Nov 15;74(22):6554-64. doi: 10.1158/0008-5472.CAN-14-1161. Epub 2014 Nov 4. Cancer Res. 2014. PMID: 25371412 Free PMC article.

In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations - PubMed (original) (raw)